Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
Valuation and Earnings
This table compares Aurinia Pharmaceuticals and Cardio Diagnostics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $283.05 million | 7.67 | $287.20 million | $2.29 | 7.08 |
| Cardio Diagnostics | $10,000.00 | 495.80 | -$6.50 million | ($2.92) | -0.57 |
Aurinia Pharmaceuticals has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Aurinia Pharmaceuticals and Cardio Diagnostics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 3 | 3 | 1 | 2.71 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Aurinia Pharmaceuticals presently has a consensus target price of $18.25, suggesting a potential upside of 12.58%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Aurinia Pharmaceuticals is more favorable than Cardio Diagnostics.
Risk & Volatility
Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500.
Institutional and Insider Ownership
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Aurinia Pharmaceuticals and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | 97.68% | 22.99% | 17.99% |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
Summary
Aurinia Pharmaceuticals beats Cardio Diagnostics on 13 of the 15 factors compared between the two stocks.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
